Emerging Generic Drug Companies Worldwide 2007

Summary

The pace of corporate consolidation grows ever faster - eight significant acquisitions were announced in 2006:

• Target
• Andrx, Mayne Pharma, Betapharm, Pliva, Matrix, Zentiva, Terapia, Hemofarm, Sindan Buyer
• Watson, Hospira, Dr Reddy's, Barr Pharmaceutical, Mylan Labs, sanofi-aventis, Ranbaxy, Stada Arzneimittel, Actavis

Increasingly the industry is being rationalised and dominated by fewer and fewer large players. Teva and Sandoz may be fighting it out for the top spot but the speed of change is seeing the corporate landscape change continuously.

And what about 2007? All generic companies are operating in increasingly crowded and competitive environments as far as the traditional high value markets such as the UK and USA are concerned. Focus is switching to growth markets such as France, Spain, Brazil and Italy where significant double-digit growth is forecast to 2011. With business cycles growing shorter and shorter, market entry is quicker and more reliable through acquisition and partnering.

Drivers for change In addition to ongoing expansion, there are other drivers which are causing the generic companies to consider the future:

The number of new generic drug opportunities are reducing in line with the decline in NDAs over recent years. Furthermore, the branded industry is far more aware of the potential to protect revenues by issuing early branded generics and/or new formulations.

The increasing introduction of biotech based products will present regulatory and production hurdles to generic manufacturers in the future.

Identify new business opportunities and assess risk For everyone needing to evaluate the generic industry's competitive landscape this new, thoroughly researched 350-page report Emerging Generic Drug Companies Worldwide 2007 (Published February 2007) is essential reading. Unbeatable coverage

For each company where available or appropriate

Background A summary of the company's foundation and main business interests

Product Range Details of ANDAs approved or products represented

Financial Financial performance or funding data

Strategic Alliances Details of significant marketing and supply agreements

Contact Information

Use this report to

• Identify commercial partners
• Understand the developing generic industry in key markets worldwide
• Profile the competitive environment in the increasingly important medium sized company sector
• Seek out companies manufacturing/marketing similar product lines
• Assess the investment potential of these developing companies

145 companies from 37 countries evaluated

• Abdi Ibrahim
• Abraxis BioScience
• Abrika Pharmaceuticals
• Ache
• Adcock Ingram
• Akorn
• Akrikhin
• Akyma Pharmaceuticals
• Alembic
• Alternova
• Amphastar Pharmaceuticals
• Andromaco
• Antibiotice
• Aurobindo Pharma
• Australian Pharmaceutical Industries
• Banner Pharmacaps
• Bedford Laboratories
• Belupo
• Bentley Pharmaceuticals
• Bestpharma
• Beximco Pharma
• Bilim Pharmaceuticals
• Biocon
• Biogaran
• Biolab
• Bio-nucleonics Pharma
• Biosano
• Biosintetica
• Biotika
• Boca Pharmacal
• Bryntsalov
• Calox
• Caraco Pharmaceutical Laboratories
• Carolina Medical Products Company
• CCL
• Cedar Pharmaceuticals
• Cedarburg Pharmaceuticals
• Cimed
• Cofasa
• Consilient Health
• Copyfarm
• CorePharma
• Cristalia
• Dr Raza Pharma
• Ecar
• EIPICo
• Elter
• EMS-Sigma
• Enaleni Pharmaceuticals
• Epla Labs
• Erka farm
• Eurand
• Eurofarma
• Europharm
• Farmacon
• Farmasa
• Farmindustria
• Ferndale Laboratories
• Fleming & Company Pharmaceuticals
• Fougera
• G&W Laboratories
• GeneMedix
• Genepharm
• Genfar
• Glades Pharmaceuticals
• Glenmark Pharmaceuticals
• Goldshield
• Grindeks
• Hamilton Laboratories
• Hanford Manufacturing
• Harmony Labs
• Highnoon Laboratories
• Hikma
• Hi-Tech Pharmacal
• Hovione FarmaCiencia
• Impax Laboratories
• Infarmasa
• Inno Biologics
• Interpharm
• Invagen Pharmaceuticals
• JB Chemicals & Pharmaceuticals
• Jubilant Organosys
• Kent Pharmaceuticals
• Kimia
• Kimiceg
• Kremers Urban Development Company
• KV Pharmaceutical
• La Sante
• Labopharm
• Laboratorios Kendrick
• Laboratorios Silanes
• Laboratorios Stein
• Lafrancol
• Leti
• Libbs Farmaceutica
• Luitpold Pharmaceuticals
• Lupin Laboratories
• Lyne Laboratories
• Mallinckrodt
• Matrix Laboratories
• Maver
• Medley
• Mepha Pharma
• Meyer
• Mikart
• Mintlab
• MN Pharmaceuticals
• Morton Grove Pharmaceuticals
• Natco Pharma
• Neil Laboratories
• Nephron Pharmaceuticals
• Orbus
• Orchid Chemicals & Pharmaceuticals
• Osmotica Pharmaceutical
• Paddock Laboratories
• Parenta Pharmaceuticals
• Pharmaceutical Associates
• Prometheus Laboratories
• ProStrakan
• Recip, ab
• Rosemont Pharmaceuticals
• Roxane Laboratories
• RxElite
• Sanitas
• Sigma Pharmaceuticals
• Silarx Pharmaceuticals
• Sopharma
• Spear Pharmaceuticals+M68
• Spectrum Pharmaceuticals
• Spirig
• Stiefel Laboratories
• Streuli
• Strides Arcolab
• Sun Pharmaceutical Laboratories
• Supergen
• Tabuk Pharmaceutical
• Taro Pharmaceutical Industries
• Three Rivers Pharmaceuticals
• Unipharm
• United Research Laboratories/ Mutual Pharmaceutical
• Upsher-Smith Laboratories
• Veropharm
• Vista Pharmaceuticals
• Vistapharm
• X-Gen Pharmaceuticals

The generic drug industry is entering a period of radical change and restructure.

The operating environment for medium-sized generic drug manufacturers is changing rapidly as the industry matures and growth focuses on new market opportunities.

Consolidation continues to affect companies, as acquisition becomes the instrument of choice in the drive for market share.

But

• Who are the medium-sized companies of note?
• How well do they perform?
• What products do they produce?
• Where are they located?

This report will tell you!

Contents

• Overview
• Forecast launch date and five-year sales
• Filings and approval
• Sales forecasts and assumptions
• Key evaluation criteria scoring
• Competitor Analysis Ratio Score (CARS)
  • (1) Novelty/rationale for mechanism of action
  • (2) Proof of concept/clinical data
  • (3) Management/clinical expertise
  • (4) Competition within the marketplace/gaining share of voice
  • (5) Risks associated with developing a drug within a therapeutic class
• Status summary for primary indications
• Development timeline;
• Potential competitors;
• Other indications and development stages;
• Development tracker;
• Research methodolog